The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Chris Molloy on building on Parliament Day's momentum, TechBio's breakthrough week, the Oxford-to-Cambridge expansion, and driving global investor confidence at the Leadership Summit
In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.
The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.
I’m pleased to share that we are part of a new Government and industry joint taskforce to drive innovation in the UK’s commercial environment for medicines, announced last week as part of government ambitions for the Life Sciences Strategy.
In this blog, Jane Wall, Managing Director at BIA, reflects on the insights from our sell-out Women in Biotech 'Big WiB' event held at Hinxton Hall, Cambridge, in the lead-up to International Women’s Day.
What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.
In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity.
The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.
We’re excited to launch She Steers, NEDs in Biotech, a specialist Non-Executive Director (NED) board programme created for women across life sciences and biotech.
J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.
This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.
Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.
Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026.
